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Abstract The concentration of copeptin, the C-terminal part
of pro-arginine vasopressin, has been shown to increase early
after acute and severe events. Owing to complementary path-
ophysiology and kinetics, the unspecific marker copeptin, in
combination with highly cardio-specific troponin, has been
evaluated as an early-rule-out strategy for acute myocardial
infarction in patients presenting with signs and symptoms of
acute coronary syndrome. Overall, most studies have reported
a negative predictive value between 97 and 100 % for the
diagnosis of acute myocardial infarction in low- to
intermediate-risk patients with suspected acute coronary syn-
drome. Additionally, a recent multicenter, randomized process
study, where patients who tested negative for copeptin and
troponin were discharged from the emergency department,
showed that the safety of the new process was comparable
to that of the current standard process. Further interventional
trials and data from registries are needed to ensure the effec-
tiveness and patient benefit of the new strategy.
Keywords Copeptin . Troponin . Rule-out . Acute
myocardial infarction . Acute coronary syndrome
Introduction
Ever since Reichlin et al. [1] published their article entitled
“Incremental value of copeptin for rapid rule-out of acute
myocardial infarction” in 2009, the concept of a single, com-
bined troponin and copeptin test at admission in patients with
suspected acute coronary syndrome (ACS) has been tested
and reported in an increasing number of publications, with
conflicting results and conclusions.
Copeptin is the C-terminal part of pro-arginine vasopressin.
Vasopressin is an important hormone for water homeostasis, but
has a very short half-life and is unstable in vitro, whichmakes its
quantification difficult. The function of copeptin remains un-
known, but it is secreted in equimolar quantities as vasopressin
and has the advantage of high stability in blood samples.
Owing to its involvement in the ACTH cycle, copeptin has
been proposed to be a marker of severe stress reactions on top
of the hemodynamic triggers mentioned above. The data base
for this assumption is scarce [2].
The pathophysiological model of acute myocardial infarc-
tion (AMI) rule-out is straightforward. Copeptin is an unspe-
cific marker but its concentration increases early on an acute
event such as AMI, most probably owing to the drop in
cardiac output and/or blood pressure. Troponin, on the other
hand, has 100 % cardio-specificity, but its concentration takes
time to increase after myocardial necrosis has occurred. To
ensure there is ischemia-related myocardial necrosis, the uni-
versal definition of AMI requires “a rise and/or fall of cardiac
biomarker values [preferably cardiac troponin (cTn)] with at
least one value above the 99th percentile upper reference limit
(URL)” [3], and thus serial troponin measurements within a
timeframe of 3–6 h. As a consequence, a positive test result for
either marker at presentation cannot be used to confirm the
diagnosis of AMI. The strength of the combined marker
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strategy with copeptin and troponin is the very early rule-out
of myocardial infarction with a single blood draw, as copeptin
and troponin should cover all time frames after the acute
event.
This article summarizes the evidence on the added value of
copeptin as a rule-out marker for AMI in patients with
suspected ACS to evaluate whether this pathophysiological
model holds true in clinical application.
The Clinical Need
Acute chest pain is one of the most frequent chief complaints
in internal emergency medicine. In the CHARITEM study,
which analyzed data of 34,333 internal emergency patients of
a German University hospital, 11.5 % (n=3,954) of the pa-
tients presented with a leading symptom of chest pain. Of
these, 47.5 % (n=1,879) were admitted to the hospital, but
only half of them where diagnosed with an ACS, and only
21.4 % (n=402) had a final diagnosis of AMI. This means for
the 3,954 patients presenting with chest pain, the frequency of
AMI was as low as 10.2 % [4•]. In a study by Goodacre et al.
[5] from the UK, 6 % (n=6.957) of all emergency patients
presented with chest pain, of which 11.0 % had ECG evidence
of ACS and 34.5 % had clinically diagnosed ACS. In patients
admitted to the hospital (n=4,438), 16.1 % had ECG evidence
of ACS and 48.6 % had clinically diagnosed ACS. In the
USA, chest pain was the second leading reason (5.4 %) for
emergency department (ED) visits in 2010. A principal hos-
pital discharge diagnosis of ischemic heart disease was
assigned to 2.9 % of all ED visits [6].
Even though not all chest pain patients will cause the treating
physician to suspect ACS and even though ACS also needs to
be suspected in many patients with symptoms other than chest
pain, these numbers emphasize the clinical need for an early
and fast rule-out of AMI. Under the current standard process of
evaluating these patients, a minimum stay of between 3 and 9 h
is mandatory. Given that the vast number of these stays are
ultimately unnecessary, personnel and space resources are
wasted in the ED and patients are left to wait until the possible
diagnosis of a “heart attack” has dissolved. In times of increas-
ing ED crowding, which has been shown to negatively impact
patient outcome [7], this process is basically unacceptable.
The Current Evidence
The two hallmark articles on copeptin in patients with
suspected ACS were published by Reichlin et al. [1] and
Keller et al. [8] (Table 1).
Reichlin et al. [1] first hypothesized “that the combination
of a marker of cardiac necrosis, such as troponin, with a
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endogenous stress, such as copeptin, might allow for a rapid
and accurate rule out of AMI already at initial presentation
without serial blood sampling.” To do so, they enrolled 492
patients with symptoms suggestive of AMI in an ED in
Switzerland and collected blood samples at presentation and
after 3 h and 6–9 h, which were tested for troponin T and
copeptin. They showed that copeptin levels were significantly
higher in patients with AMI than in patients with other diag-
noses, including unstable angina. Copeptin levels were partic-
ularly high in AMI-patients who tested negative for troponin T
values at presentation and in patients who presented within 0–
4 h after the onset of symptoms. With use of cutoff values of
0.01 μg/l or less for troponin T and less than 14 pmol/l for
copeptin, the combined use of these two markers at presenta-
tion yielded a negative predictive value (NPV) for the diag-
nosis of non-ST-segment-elevation myocardial infarction
(NSTEMI) of 99.7 %.
Keller et al. [8] confirmed these findings in a chest pain unit
(CPU) population of 1,386 patients with chest pain or equiv-
alent symptoms, where the marker combination at the 99th
percentile cutoff for sensitive troponin I and 9.8 pmol/l for
copeptin showed an NPVof 99 % (95 % confidence interval
96.6–99.9 %). Additionally, they reported the results of serial
blood sampling in a subgroup of patients who presented
within 2 h after symptom onset to illustrate the complemen-
tary kinetics of troponin T, the concentration of which in-
creased 6 h after admission, and copeptin, the concentration
of which decreased during the first 6 h after a peak at presen-
tation, in patients with AMI.
Since then, many articles have been published, partly
confirming and partly contradicting these findings. To be able
to correctly judge these publications, a number of factors have
to be considered.
The Copeptin Cutoff
Keller et al. [8] evaluated different potential cutoff values for
copeptin in a large reference population (n=5,000), where the
99th percentile cutoff value was 18.9 pmol/l, the 97.5th per-
centile value was 13 pmol/l, and the 95th percentile value
was9.8 pmol/l. Most clinical studies used a copeptin cutoff of
14 pmol/l. This cutoff was driven by the first copeptin assay
available, which did not allow quantification of copeptin below
this value [lower detection limit 4.8 pmol/l, functional assay
sensitivity (lowest value with an interassay coefficient of var-
iation below 20 %) below 12 pmol/l, limit of quantification
14.1 pmol/l] (manufacturer’s data). In 2011, an ultrasensitive
copeptin assay was released, exhibiting a lower detection limit
of less than 1 pmol/l, a functional assay sensitivity of less than 2
pmol/l, and a value for a coefficient of variation of 10 % of 2.5
pmol/l (manufacturer’s data). Mainly because 14 pmol/l was
used in the first publications, this cutoff is still used in most
studies. The lower the cutoff value though, the higher is the
NPV for the diagnosis of AMI. To minimize the number of
false-negative patients, a 95th percentile value (10 pmol/l)
might be advisable. Table 2 shows a number of copeptin studies
where different cutoff values were used, for comparison.
AMI Prevalence and Pretest Probability
Although sensitivity and specificity are independent of the
prevalence of the disease, both the positive predictive value
and the NPV change with different disease prevalence. The
NPV decreases with increasing prevalence, whereas the pos-
itive predictive value increases. In most rule-out studies on
copeptin and troponin, the NPV is the primary measure of
interest, determining success or failure of the new concept.
Table 1 provides a list of studies with their respective AMI
prevalence and the NPV calculated for this population.
Even though the data are difficult to compare for the
multitude of factors influencing the study results, the data
reflect a relatively low NPV in cohorts with an AMI preva-
lence above 20 % (Table 3).
For the same reason, a test can exhibit very different
predictive values when it is administered to patients at differ-
ent levels of risk (Table 4). Again, in a high-risk population
the NPVis lower, whereas it is higher in a low-risk population.
The marker combination of troponin and copeptin has been
shown to achieve the best results in patients at low- to inter-
mediate risk of AMI. Bohyn et al. [19••] tested a rule-out
strategy using copeptin, troponin, and the Global Registry of
Acute Coronary Events (GRACE) score. Here, both markers
had to test negative and the GRACE score had to be below
108 points. With this concept, the NPV was 99 % (95 %
confidence interval 94–100 %).
Two studies have shown that the pretest probability can
also be determined by the judgment of the treating physician.
Chenevier-Gobeaux et al. [20••] divided their cohort into
three pre-test-probability groups (low, medium, or high), as
assessed by the treating ED physician after the first clinical
evaluation but before the biomarker results were available.
The NPVs were 100 (78-100)% in high-risk patients, 98 (87-
100)% in medium-risk patients, and 100 (95-100)% in low-
risk patients. In the CHOPIN study [22••], the treating ED
physicians were asked to judge the likelihood of ACS and
AMI on a visual analogue scale. The NPV for patients with
intermediate risk was 99.6 % and for patients with low risk
was 99.8 %;the NPV for the entire cohort was 99.2 %.
Time Point of Blood Sampling
The concentration of copeptin is known to increase with the
acute event and to then decrease rapidly to normal values
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within hours [8]. Thus, the time point of copeptin testing is
crucial for this concept. In studies with most patients present-
ing late after the onset of symptoms, copeptin testing is
unlikely to provide added value to troponin testing, as most
patients will already be troponin-positive at admission to the
ED or CPU [23•]. This was taken to an extreme in a study by
Karakas et al. [24•] where copeptin was measured at a median
of 4.3 h after presentation to the ED in a study which was
primarily set up to evaluate CT angiography in patients with
suspected ACS.
It is important to note that in late presenters the new
strategy of a single copeptin–troponin measurement at presen-
tation does not harm the patient, as the concentration of
troponin will at this stage be increased in patients with
NSTEMI and discharge of false-negative patients is thus
unlikely.
Study End Point
Some studies have evaluated the diagnostic performance of
copeptin and troponin for the diagnosis of ACS rather than the
diagnosis of AMI [24•, 25•, 26•]. Reichlin et al. [1] clearly
showed that the concentration of copeptin is not increased in
patients with unstable angina.
The combined marker strategy also seems to perform better
in cohorts with NSTEMI patients as compared with all AMIs
[27•]. Nevertheless, given that the diagnosis in ST-segment-
elevation myocardial infarction (STEMI) is based on ECG
rather than biomarker results, STEMI patients have often been
excluded when the diagnostic performance of these markers has
been analyzed. Specifically, in unclear situations when patients
present early, there is also a potential benefit of copeptin testing
for patients who are finally categorized as having STEMI.
Application of the New Strategy in Clinical Practice
All the aforementioned studies are observational studies with
retrospective copeptin measurement, where the copeptin value
did not change patient care. Recently, the BIC-8 study, the first
interventional, randomized process trial, evaluating the early-
rule-out strategy in clinical practice, has been published
[28••]. Low- to intermediate-risk patients with suspected
ACS (n=902) were randomized into either the standard group,
receiving standard diagnostic workup and care, or the
copeptin group, where further care depended on the copeptin
value. In this group, copeptin-positive patients were consid-
ered higher risk and were admitted for standard workup,
whereas copeptin-negative patients were considered low risk
and were discharged to ambulant care, including a visit with a
resident cardiologist within three working days. Importantly,
the ultimate decision to discharge or admit a patient was left to
the discretion of the treating physician on the basis on his/her
clinical workup.
In this multicenter, international study, the major adverse
cardiac event proportion at 30 days was not higher in the
copeptin group (5.17 %) as compared with the standard group
(5.19 %), suggesting safety comparable to that of the current
standard process. Secondary end point analysis showed that
patients in the copeptin group were discharged directly from
the ED/CPU more often (67.6 % in the copeptin group vs
12 % in the standard group) and earlier (median length of stay
for patients with AMI exclusion 4 h in the copeptin group and
7 h in the standard group), suggesting an effectiveness benefit
of the new process.
Conclusion
There is ample evidence that combined testing of copeptin and
troponin at presentation in low- to intermediate-risk patients
with suspected ACS to rule out NSTEMI is a promising
strategy. From a review of publications on this new concept,
all the aforementioned factors—copeptin cutoff, pretest prob-
ability, and time point of copeptin testing—need to be consid-
ered to be able to judge the results appropriately.
When applying the strategy in clinical practice, physicians
need to be aware that copeptin–troponin rule-out should be
applied only in patients at low-to intermediate risk of ACS
who are generally fit to be discharged. It is important to keep
in mind that biomarkers, like all diagnostic tests, need to be
applied with an appropriate objective, on the basis of a thor-
ough clinical workup to be able to interpret the results correctly.
BIC-8 has indicated that low-to intermediate-risk patients
with a negative copeptin–troponin marker combination can be
safely discharged. Figure 1 shows a flowchart for the sug-
gested new process of an ACS workup. Still, clinical process
studies are faced with a number of issues limiting the evalu-
ation of a single step in a network of influencing factors and
decisions. Thus, the results of this trial should be confirmed in
further interventional trials. If the process is implemented in
Fig. 1 Suggested new process for the workup of low- to intermediate-
risk patients with suspected acute coronary syndrome (ACS) using an
early rule-out strategy with combined troponin and copeptin testing
421, Page 6 of 8 Curr Atheroscler Rep (2014) 16:421
clinical practice, outcomes of patients managed with the new
process strategy should be monitored closely in clinical reg-
istries to be able to judge the real-life safety and effectiveness.
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